ClinicalTrials.gg
CompletedNCT05820204Updated Oct 27, 2026Results posted

Acceptability and Efficacy of Pain Reprocessing Therapy in Racially/ Ethnically Diverse Adults With Chronic Back Pain

An interventional study of Pain reprocessing therapy (PRT) and Cognitive Behavioral Therapy for Chronic Pain (CBT-CP) in Pain, Chronic and Back Pain, sponsored by Weill Medical College of Cornell University. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Weill Medical College of Cornell University · Not applicable, Interventional, and Treatment

How we know

Updated Oct 27, 2026Now CompletedResults posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
165
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 18 studies in Chronic Pain by Weill Medical College of Cornell University — 5 open to participants now, 6 under way, none of them phase 3. Chronic Pain · Weill Medical College of Cornell University.

Enrollment
3rd of 15
165 · median 95
Started
2023
with 2 others
No phase
13 of 18
3 open now
Registered
13th of 18
by date

Among the 18 studies in Chronic Pain by Weill Medical College of Cornell University, this one is the 3rd largest by enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2023, is one of 13 with no phase, and was the 13th registered.

Chronic Pain

3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

5 of the 18 studies in Chronic Pain by Weill Medical College of Cornell University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Chronic Pain by Weill Medical College of Cornell University, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn which treatment works better for adults with chronic pain. This study is comparing three treatments: Pain Reprocessing Therapy (PRT), Cognitive Behavioral Therapy (CBT), and usual care (whatever a person is already doing to cope with their pain).

The study's main questions are:

  • Does PRT work well for adults with chronic pain?
  • Which treatment works better for lowering pain: PRT, CBT, or usual care?

This study will compare PRT, CBT, and usual care to see which is most helpful for lowering pain and helping with other problems that people with chronic pain can have.

Read the detailed description

Investigators recently developed a novel psychological treatment, pain reprocessing therapy (PRT). Using a combination of cognitive, exposure-based, and somatic psychotherapy techniques, PRT aims to promote patients' reconceptualization of pain as due to reversible, non-dangerous brain activity rather than peripheral pathology. Critically, PRT aims to reduce or eliminate pain, rather than increasing functioning.

In the first trial of PRT (N = 151), 66% of patients randomized to PRT were pain-free or nearly so at post-treatment, as compared to fewer than 20% of placebo and usual care controls. This trial was conducted in a primarily White, highly-educated population with face-to-face treatment, and how PRT effects would generalize to a more diverse population or to telehealth treatment is not known.

PRT was developed to better address pain intensity and pain-related outcomes compared to leading psychological treatments for pain such as cognitive behavioral therapy (CBT). This study aims to yield preliminary findings on the comparative efficacy of PRT vs. CBT vs. usual care. Developing scalable effective, non-pharmacological chronic pain treatments and testing their efficacy in racial/ethnic minorities is an urgent societal need. Accordingly, this study also tests a remotely-delivered PRT intervention in a diverse patient population.

Aim 1 of this study is to test the feasibility (recruitment \& retention) of conducting a randomized clinical trial comparing remotely-delivered PRT with an active comparator, CBT, and usual care and to assess the acceptability (helpfulness, satisfaction, \& impact) of PRT in a diverse, lower socioeconomic status (SES) patient population.

Aim 2 of this study is to test the comparative efficacy of PRT vs. CBT and PRT vs. usual care on pain intensity and other pain-related outcomes.

Additional resources became available during the study, allowing an increase in sample size from N = 75 to N = 150 to provide greater statistical power aim 2 (comparative efficacy). No interim analyses were conducted at any point, and investigators remained blind to study outcomes. The decision to expand the sample size was made after careful deliberation with Columbia and Cornell Roybal Center Advisory Committees.

03

Conditions studied

  • Pain, Chronic
  • Back Pain

Keywords

  • chronic pain
  • Pain Reprocessing Therapy
  • Cognitive Behavioral Therapy for Chronic Pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Last-week average back pain of at least 4 of 10 at the two pretreatment timepoints (online pre-screening and session)
  • Back pain that is an ongoing problem for at least half the days of the last 6 months
  • Back pain that is worse than leg pain.

Exclusion criteria

Exclusion Criteria:

  • Current litigation or compensation associated with pain or plans to apply for compensation or engage in litigation in the next 6 months
  • Active suicidal ideation with intent, recent history of suicide attempt, or recent history of suicide attempts or self-harm behaviors within the past 5 years (including non-suicidal self-harm)
  • Recent history of inpatient psychiatric hospitalization within the past 5 years
  • Active, current psychosis or mania
  • Active, current substance abuse, or problems with substance abuse within the past 2 years
  • Instability in living conditions or major interfering life events:

    • Major surgery or other major medical event planned in coming six months
    • Unsure whether will reliably have suitable conditions for telehealth appointments over the next two months, including a computer or tablet, reliable fast internet, and a quiet comfortable room that is reliably available.
    • Major, interfering changes in employment or housing anticipated over the next six months
  • Failure to complete at least 85% (6 of 7) of EMA surveys in the first week of the study (post-consent, pre-randomization)
  • Leg pain worse than back pain
  • Back surgery within the last 2 years
  • Difficulty controlling bladder function (to screen out cauda equina syndrome)
  • Serious medical illness (e.g., current, or recent cancer diagnosis, severe cardiovascular disease)
  • Recent large unexplained, unintended weight loss (20lbs or more)
  • Recent vertebral fracture/ known spinal fractures or tumors
  • Known sensory/motor abnormalities in the trunk or legs.
  • Self-reported diagnosis of a specific inflammatory disorder: rheumatoid arthritis, polymyalgia rheumatica, scleroderma, Lupus, or polymyositis
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
165 participants (actual)

Study arms

  • Experimental
    Pain reprocessing therapy (PRT)

    PRT has 5 components: 1) education about the origin of pain in the brain, its reversibility, and the pain-fear cycle; 2) reinforcing education using personal biography; 3) "somatic tracking" of pain through mindfulness and reappraisal of pain sensations as non-dangerous; 4) lowering the level of personal threat that may trigger pain sensation; and 5) inducing positive affect in periods of pain. Patients will attend 1 assessment and education telehealth session with a physician followed by 8, 50-minute, therapist-led sessions. Pacing will be flexible, ranging from 5-12 weeks, to increase accessibility. Treatment will be provided by experienced PRT clinicians. All PRT sessions will be remotely-delivered.

    Behavioral: Pain reprocessing therapy (PRT)

  • Active comparator
    Cognitive Behavioral Therapy for Chronic Pain (CBT-CP)

    CBT-CP, considered the leading psychological treatment for chronic pain, is a structured, time-limited intervention that aims to teach patients how to better manage chronic pain and improve their quality of life. Participants will receive 9, 50-minute sessions of CBT-CP over 5 - 12 weeks. The VA CBT-CP protocol contains an initial orientation involving education and familiarization with the CBT-CP approach to chronic pain. The protocol then includes sessions that focus on topics such as exercise, relaxation, pleasant activities, cognitive coping, and sleep. All CBT-CP sessions will be remotely-delivered.

    Behavioral: Cognitive Behavioral Therapy for Chronic Pain (CBT-CP)

  • Active comparator
    Usual Care

    Participants will be asked to continue whatever they are already doing to care for their back pain. Length of the usual care condition will be 5 weeks, the expected mean completion time of the PRT and CBT arms, and may be adjusted at mid-enrollment to match treatment arm length more closely.

    Other: Usual care

Interventions

  • BehavioralPain reprocessing therapy (PRT)

    A promising new psychotherapy for chronic pain

  • BehavioralCognitive Behavioral Therapy for Chronic Pain (CBT-CP)

    A psychotherapy for chronic pain that has 30+ years of research support.

    Also known as: Cognitive Behavioral Therapy

  • OtherUsual care

    Participants will be asked to continue to do whatever they are currently doing to manage their pain

    Also known as: Treatment as usual

06

What researchers measure

Primary outcomes

  1. Pain Intensity

    Last-week average pain intensity is assessed via the Brief Pain Inventory Short Form (BPI-SF). The BPI-SF assess pain severity and its impact on functioning. It consists of 9 total items including 4 pain items and 5 pain interference items. The 4 pain items measure pain in the last week on a numerical rating scale of 0 (no pain at all) to 10 (pain as bad as you can imagine). The reported score is the mean of the 4 pain items, yielding a total range of 0-10, with higher scores indicating greater pain severity.

    Time frame: Primary time point is the day after post-treatment, 1.5 months on average

  2. Session Attendance

    Session attendance is a feasibility measure calculated as the percentage of people randomized to either PRT or CBT who attended at least 6 sessions.

    Time frame: Assessed the day after post-treatment, an average of 1.5 months after randomization.

Secondary outcomes

  1. Pain Interference

    Pain interference is assessed via the 5 pain interference items of the Brief Pain Inventory Short Form (BPI-SF). The BPI-SF assesses pain severity and its impact on functioning. It consists of 9 total items including 4 pain items and 5 pain interference items. The 5 pain interference items measure pain interference in the last week on a numerical rating scale of 0 (does not interfere) to 10 (completely interferes). The reported score is the mean of the 5 pain interference items, yielding a total range of 0-10, with higher scores indicating greater pain interference.

    Time frame: Primary time point is the day after post-treatment, 1.5 months on average

  2. Depression

    Depression is assessed via the 8-item depression sub-scale of the Patient Reported Outcome Measurement Information System Short Form (PROMIS-SF), rated on a 5-point scale of 1 (never) to 5 (always). Raw scores (range 8-40) are converted to a T-score (mean 50, SD 10, U.S. general population norm); T-scores for this form range from 38.2 to 81.3, with higher scores indicating greater depressive symptoms.

    Time frame: Primary time point is the day after post-treatment, 1.5 months on average

  3. Positive Affect

    Positive affect is assessed via the 5-item Positive Affect subscale (Attentive, Active, Alert, Inspired, Determined), asking respondents to indicate the extent to which each word describes how they felt in the past week. Each item is rated on a 5-point scale of 1 (very slightly or not at all) to 5 (extremely). Scores are summed across the 5 items, yielding a possible range of 5 to 25. A score of 5 indicates the lowest possible level of positive affect; a score of 25 indicates the highest possible level of positive affect.

    Time frame: Primary time point is the day after post-treatment, 1.5 months on average

  4. Anxiety

    Anxiety is assessed via the 8-item anxiety sub-scale of the Patient Reported Outcome Measurement Information System Short Form (PROMIS-SF), rated on a 5-point scale of 1 (never) to 5 (always). Raw scores (range 8-40) are converted to a T-score (mean 50, SD 10, U.S. general population norm); T-scores for this form range from 37.1 to 83.1, with higher scores indicating greater anxiety.

    Time frame: Primary time point is the day after post-treatment, 1.5 months on average

  5. Anger

    Anger is assessed via the 5-item anger sub-scale of the Patient Reported Outcome Measurement Information System Short Form (PROMIS-SF), rated on a 5-point scale of 1 (never) to 5 (always). Raw scores (range 5-25) are converted to a T-score (mean 50, SD 10, U.S. general population norm); T-scores for this form range from 32.9 to 82.9, with higher scores indicating greater anger.

    Time frame: Primary time point is the day after post-treatment, 1.5 months on average

  6. Sleep Disturbance

    Sleep disturbance is assessed via the 8-item sleep disturbance sub-scale of the Patient Reported Outcome Measurement Information System Short Form (PROMIS-SF), rated on 5-point item-specific scales. Raw scores (range 8-40) are converted to a T-score (mean 50, SD 10, U.S. general population norm); T-scores for this form range from 30.5 to 77.5, with higher scores indicating greater sleep disturbance.

    Time frame: Primary time point is the day after post-treatment, 1.5 months on average

  7. Client Satisfaction

    Client Satisfaction is assessed the Patients' Global Impression of Change (PGIC). The PGIC is a single-item self-report scale that measures a patient's belief about the efficacy of treatment. The single-item is rated on a 7-point scale of 0 (No change or condition has got worse) to 6 (a great deal better).

    Time frame: Primary time point is the day after post-treatment, 1.5 months on average

  8. Change in Pain Medication Use

    Medication use is assessed by asking participants to provide the names, dosages, and frequencies of the medications that they are currently taking for pain management only. A blinded research assistant reviewed pre- and post-treatment responses and manually coded each participant as increasing, decreasing, or no change with regards to overall pain medication burden (number of pain medications, dose, frequency, and class: opioid \> prescription \> OTC). Cases with insufficient or unreliable data were excluded (e.g., a participant with multiple medications reported at baseline but none at post-treatment, suggestive of missing data).

    Time frame: Primary time point is the day after post-treatment, 1.5 months on average

07

Results

Posted Oct 27, 2026

Participant flow

Participants were recruited via provider referral from primary care and pain medicine clinics affiliated with academic medical centers, and from community and religious centers serving diverse communities, supplemented by online recruitment (e.g., ResearchMatch, BuildClinical, Facebook) to support enrollment of a racially/ethnically diverse sample. Recruitment occurred at University of Colorado Anschutz Medical Campus (Aurora, CO).

Participant flow — Overall Study
MilestonePain Reprocessing Therapy (PRT)Cognitive Behavioral Therapy for Chronic Pain (CBT-CP)Usual Care
Started505050
Initiated treatment46470
Completed treatment39400
Withdrew from treatment, continued surveys340
Observed at mid-treatment424547
Completed414547
Not completed953
Withdrew: Withdrawal by subject323
Withdrew: Lost to follow-up630

Outcome measures

PrimaryPain Intensity

Last-week average pain intensity is assessed via the Brief Pain Inventory Short Form (BPI-SF). The BPI-SF assess pain severity and its impact on functioning. It consists of 9 total items including 4 pain items and 5 pain interference items. The 4 pain items measure pain in the last week on a numerical rating scale of 0 (no pain at all) to 10 (pain as bad as you can imagine). The reported score is the mean of the 4 pain items, yielding a total range of 0-10, with higher scores indicating greater pain severity.

Time frame:
Primary time point is the day after post-treatment, 1.5 months on average
Reported as:
Mean · units on a scale
Pain Intensity
units on a scalePain Reprocessing Therapy (PRT)Cognitive Behavioral Therapy for Chronic Pain (CBT-CP)Usual Care
Baseline5.52 ± 0.215.39 ± 0.215.34 ± 0.2
Post-Treatment2.28 ± 0.254.33 ± 0.244.84 ± 0.24
Statistical analysis
  • Pain Reprocessing Therapy (PRT) vs Cognitive Behavioral Therapy for Chronic Pain (CBT-CP) · Mixed Models Analysis · p = <0.001 (A priori alpha = .05, Holm-Bonferroni corrected for multiple comparisons (PRT vs. CBT, PRT vs. usual care). Model adjusted for age and sex.) · Mean difference (net): -2.01 · 95% CI -2.65 to -1.37Piecewise mixed-effects model, knot at post-treatment.
  • Pain Reprocessing Therapy (PRT) vs Usual Care · Mixed Models Analysis · p = <0.001 (A priori alpha = .05, Holm-Bonferroni corrected for multiple comparisons (PRT vs. CBT, PRT vs. usual care). Model adjusted for age and sex.) · Mean difference (net): -2.59 · 95% CI -3.22 to -1.95Piecewise mixed-effects model, knot at post-treatment.
PrimarySession Attendance

Session attendance is a feasibility measure calculated as the percentage of people randomized to either PRT or CBT who attended at least 6 sessions.

Time frame:
Assessed the day after post-treatment, an average of 1.5 months after randomization.
Reported as:
Count of participants · Participants
Session Attendance
ParticipantsPain Reprocessing Therapy (PRT)Cognitive Behavioral Therapy for Chronic Pain (CBT-CP)Usual Care
Session Attendance3941—
SecondaryPain Interference

Pain interference is assessed via the 5 pain interference items of the Brief Pain Inventory Short Form (BPI-SF). The BPI-SF assesses pain severity and its impact on functioning. It consists of 9 total items including 4 pain items and 5 pain interference items. The 5 pain interference items measure pain interference in the last week on a numerical rating scale of 0 (does not interfere) to 10 (completely interferes). The reported score is the mean of the 5 pain interference items, yielding a total range of 0-10, with higher scores indicating greater pain interference.

Time frame:
Primary time point is the day after post-treatment, 1.5 months on average
Reported as:
Mean · units on a scale
Pain Interference
units on a scalePain Reprocessing Therapy (PRT)Cognitive Behavioral Therapy for Chronic Pain (CBT-CP)Usual Care
Baseline4.87 ± 0.285.26 ± 0.274.95 ± 0.26
Post-Treatment1.47 ± 0.33.6 ± 0.34.25 ± 0.29
Statistical analysis
  • Pain Reprocessing Therapy (PRT) vs Cognitive Behavioral Therapy for Chronic Pain (CBT-CP) · Mixed Models Analysis · p = <0.001 (A priori alpha = .05, Holm-Bonferroni corrected for multiple comparisons (PRT vs. CBT, PRT vs. usual care). Model adjusted for age and sex.) · Mean difference (net): -1.75 · 95% CI -2.52 to -0.97Piecewise mixed-effects model, knot at post-treatment.
  • Pain Reprocessing Therapy (PRT) vs Usual Care · Mixed Models Analysis · p = <0.001 (A priori alpha = .05, Holm-Bonferroni corrected for multiple comparisons (PRT vs. CBT, PRT vs. usual care). Model adjusted for age and sex.) · Mean difference (net): -2.59 · 95% CI -3.35 to -1.82Piecewise mixed-effects model, knot at post-treatment.
SecondaryDepression

Depression is assessed via the 8-item depression sub-scale of the Patient Reported Outcome Measurement Information System Short Form (PROMIS-SF), rated on a 5-point scale of 1 (never) to 5 (always). Raw scores (range 8-40) are converted to a T-score (mean 50, SD 10, U.S. general population norm); T-scores for this form range from 38.2 to 81.3, with higher scores indicating greater depressive symptoms.

Time frame:
Primary time point is the day after post-treatment, 1.5 months on average
Reported as:
Mean · T-score
Depression
T-scorePain Reprocessing Therapy (PRT)Cognitive Behavioral Therapy for Chronic Pain (CBT-CP)Usual Care
Baseline54.47 ± 1.5253.37 ± 1.3653.37 ± 1.31
Post-Treatment48.56 ± 1.2650.54 ± 1.2551.8 ± 1.23
Statistical analysis
  • Pain Reprocessing Therapy (PRT) vs Cognitive Behavioral Therapy for Chronic Pain (CBT-CP) · Mixed Models Analysis · p = 0.06 (A priori alpha = .05, Holm-Bonferroni corrected for multiple comparisons (PRT vs. CBT, PRT vs. usual care). Model adjusted for age and sex.) · Mean difference (net): -2.71 · 95% CI -5.47 to 0.06Piecewise mixed-effects model, knot at post-treatment.
  • Pain Reprocessing Therapy (PRT) vs Usual Care · Mixed Models Analysis · p = 0.01 (A priori alpha = .05, Holm-Bonferroni corrected for multiple comparisons (PRT vs. CBT, PRT vs. usual care). Model adjusted for age and sex.) · Mean difference (net): -4.13 · 95% CI -6.87 to -1.39Piecewise mixed-effects model, knot at post-treatment.
SecondaryPositive Affect

Positive affect is assessed via the 5-item Positive Affect subscale (Attentive, Active, Alert, Inspired, Determined), asking respondents to indicate the extent to which each word describes how they felt in the past week. Each item is rated on a 5-point scale of 1 (very slightly or not at all) to 5 (extremely). Scores are summed across the 5 items, yielding a possible range of 5 to 25. A score of 5 indicates the lowest possible level of positive affect; a score of 25 indicates the highest possible level of positive affect.

Time frame:
Primary time point is the day after post-treatment, 1.5 months on average
Reported as:
Mean · units on a scale
Positive Affect
units on a scalePain Reprocessing Therapy (PRT)Cognitive Behavioral Therapy for Chronic Pain (CBT-CP)Usual Care
Baseline15.58 ± 0.5615.7 ± 0.5316.08 ± 0.59
Post-Treatment18.82 ± 0.5417.72 ± 0.5316.13 ± 0.52
Statistical analysis
  • Pain Reprocessing Therapy (PRT) vs Cognitive Behavioral Therapy for Chronic Pain (CBT-CP) · Mixed Models Analysis · p = .10 (A priori alpha = .05, Holm-Bonferroni corrected for multiple comparisons (PRT vs. CBT, PRT vs. usual care). Model adjusted for age and sex.) · Mean difference (net): 1.21 · 95% CI -0.21 to 2.63Piecewise mixed-effects model, knot at post-treatment.
  • Pain Reprocessing Therapy (PRT) vs Usual Care · Mixed Models Analysis · p = <0.001 (A priori alpha = .05, Holm-Bonferroni corrected for multiple comparisons (PRT vs. CBT, PRT vs. usual care). Model adjusted for age and sex.) · Mean difference (net): 3.26 · 95% CI 1.84 to 4.67Piecewise mixed-effects model, knot at post-treatment.
SecondaryAnxiety

Anxiety is assessed via the 8-item anxiety sub-scale of the Patient Reported Outcome Measurement Information System Short Form (PROMIS-SF), rated on a 5-point scale of 1 (never) to 5 (always). Raw scores (range 8-40) are converted to a T-score (mean 50, SD 10, U.S. general population norm); T-scores for this form range from 37.1 to 83.1, with higher scores indicating greater anxiety.

Time frame:
Primary time point is the day after post-treatment, 1.5 months on average
Reported as:
Mean · T-score
Anxiety
T-scorePain Reprocessing Therapy (PRT)Cognitive Behavioral Therapy for Chronic Pain (CBT-CP)Usual Care
Baseline56.27 ± 1.556.93 ± 1.5454.27 ± 1.49
Post-Treatment52.93 ± 1.4453.23 ± 1.4352.84 ± 1.41
Statistical analysis
  • Pain Reprocessing Therapy (PRT) vs Cognitive Behavioral Therapy for Chronic Pain (CBT-CP) · Mixed Models Analysis · p = 0.59 (A priori alpha = .05, Holm-Bonferroni corrected for multiple comparisons (PRT vs. CBT, PRT vs. usual care). Model adjusted for age and sex.) · Mean difference (net): 0.73 · 95% CI -1.9 to 3.36Piecewise mixed-effects model, knot at post-treatment.
  • Pain Reprocessing Therapy (PRT) vs Usual Care · Mixed Models Analysis · p = 0.35 (A priori alpha = .05, Holm-Bonferroni corrected for multiple comparisons (PRT vs. CBT, PRT vs. usual care). Model adjusted for age and sex.) · Mean difference (net): -1.81 · 95% CI -4.41 to 0.8Piecewise mixed-effects model, knot at post-treatment.
SecondaryAnger

Anger is assessed via the 5-item anger sub-scale of the Patient Reported Outcome Measurement Information System Short Form (PROMIS-SF), rated on a 5-point scale of 1 (never) to 5 (always). Raw scores (range 5-25) are converted to a T-score (mean 50, SD 10, U.S. general population norm); T-scores for this form range from 32.9 to 82.9, with higher scores indicating greater anger.

Time frame:
Primary time point is the day after post-treatment, 1.5 months on average
Reported as:
Mean · T-score
Anger
T-scorePain Reprocessing Therapy (PRT)Cognitive Behavioral Therapy for Chronic Pain (CBT-CP)Usual Care
Baseline52.83 ± 1.5853.2 ± 1.4752.44 ± 1.49
Post-Treatment46.87 ± 1.350.21 ± 1.2750.21 ± 1.25
Statistical analysis
  • Pain Reprocessing Therapy (PRT) vs Cognitive Behavioral Therapy for Chronic Pain (CBT-CP) · Mixed Models Analysis · p = .21 (A priori alpha = .05, Holm-Bonferroni corrected for multiple comparisons (PRT vs. CBT, PRT vs. usual care). Model adjusted for age and sex.) · Mean difference (net): -2.39 · 95% CI -6.09 to 1.32Piecewise mixed-effects model, knot at post-treatment.
  • Pain Reprocessing Therapy (PRT) vs Usual Care · Mixed Models Analysis · p = .13 (A priori alpha = .05, Holm-Bonferroni corrected for multiple comparisons (PRT vs. CBT, PRT vs. usual care). Model adjusted for age and sex.) · Mean difference (net): -3.51 · 95% CI -7.19 to 0.16Piecewise mixed-effects model, knot at post-treatment.
SecondarySleep Disturbance

Sleep disturbance is assessed via the 8-item sleep disturbance sub-scale of the Patient Reported Outcome Measurement Information System Short Form (PROMIS-SF), rated on 5-point item-specific scales. Raw scores (range 8-40) are converted to a T-score (mean 50, SD 10, U.S. general population norm); T-scores for this form range from 30.5 to 77.5, with higher scores indicating greater sleep disturbance.

Time frame:
Primary time point is the day after post-treatment, 1.5 months on average
Reported as:
Mean · T-score
Sleep Disturbance
T-scorePain Reprocessing Therapy (PRT)Cognitive Behavioral Therapy for Chronic Pain (CBT-CP)Usual Care
Baseline57.6 ± 1.1757.37 ± 1.0456.42 ± 1.35
Post-Treatment50.94 ± 1.2752.31 ± 1.2654.85 ± 1.24
Statistical analysis
  • Pain Reprocessing Therapy (PRT) vs Cognitive Behavioral Therapy for Chronic Pain (CBT-CP) · Mixed Models Analysis · p = .34 (A priori alpha = .05, Holm-Bonferroni corrected for multiple comparisons (PRT vs. CBT, PRT vs. usual care). Model adjusted for age and sex.) · Mean difference (net): -1.34 · 95% CI -4.09 to 1.42Piecewise mixed-effects model, knot at post-treatment.
  • Pain Reprocessing Therapy (PRT) vs Usual Care · Mixed Models Analysis · p = .001 (A priori alpha = .05, Holm-Bonferroni corrected for multiple comparisons (PRT vs. CBT, PRT vs. usual care). Model adjusted for age and sex.) · Mean difference (net): -4.89 · 95% CI -7.62 to -2.16Piecewise mixed-effects model, knot at post-treatment.
SecondaryClient Satisfaction

Client Satisfaction is assessed the Patients' Global Impression of Change (PGIC). The PGIC is a single-item self-report scale that measures a patient's belief about the efficacy of treatment. The single-item is rated on a 7-point scale of 0 (No change or condition has got worse) to 6 (a great deal better).

Time frame:
Primary time point is the day after post-treatment, 1.5 months on average
Reported as:
Mean · units on a scale
Client Satisfaction
units on a scalePain Reprocessing Therapy (PRT)Cognitive Behavioral Therapy for Chronic Pain (CBT-CP)Usual Care
Client Satisfaction5.10 ± 1.023.69 ± 1.991.74 ± 1.76
SecondaryChange in Pain Medication Use

Medication use is assessed by asking participants to provide the names, dosages, and frequencies of the medications that they are currently taking for pain management only. A blinded research assistant reviewed pre- and post-treatment responses and manually coded each participant as increasing, decreasing, or no change with regards to overall pain medication burden (number of pain medications, dose, frequency, and class: opioid \> prescription \> OTC). Cases with insufficient or unreliable data were excluded (e.g., a participant with multiple medications reported at baseline but none at post-treatment, suggestive of missing data).

Time frame:
Primary time point is the day after post-treatment, 1.5 months on average
Reported as:
Count of participants · Participants
Change in Pain Medication Use
ParticipantsPain Reprocessing Therapy (PRT)Cognitive Behavioral Therapy for Chronic Pain (CBT-CP)Usual Care
Decrease1578
Increase015
No Change212328

Adverse events

Collected over Enrollment until end of 12-month follow-up. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pain Reprocessing Therapy (PRT)0/50 (0%)0/50 (0%)0/50 (0%)
Cognitive Behavioral Therapy for Chronic Pain (CBT-CP)0/50 (0%)0/50 (0%)0/50 (0%)
Usual Care0/50 (0%)0/50 (0%)0/50 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Pain Reprocessing Therapy (PRT)Cognitive Behavioral Therapy for Chronic Pain (CBT-CP)Usual CareTotal
Mean48.9 ± 15.150.7 ± 14.949.5 ± 15.449.7 ± 15.0
Sex: Female, Male
Sex: Female, Male(Participants)Pain Reprocessing Therapy (PRT)Cognitive Behavioral Therapy for Chronic Pain (CBT-CP)Usual CareTotal
Female29323192
Male21181958
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pain Reprocessing Therapy (PRT)Cognitive Behavioral Therapy for Chronic Pain (CBT-CP)Usual CareTotal
American Indian or Alaska Native2204
Asian5128
Native Hawaiian or Other Pacific Islander0000
Black or African American7111129
White313336100
More than one race2114
Unknown or Not Reported3205
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pain Reprocessing Therapy (PRT)Cognitive Behavioral Therapy for Chronic Pain (CBT-CP)Usual CareTotal
Hispanic or Latino52411
Not Hispanic or Latino444846138
Unknown or Not Reported1001
08

Study locations

1 site
  • University of Colorado Anschutz Medical Campus
    Aurora, Colorado 80045, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Investigators will share de-identified project data publicly under Data Use Agreements that safeguard individual participant confidentiality and privacy. The study will produce the following types of data. All data will be available for sharing, except where noted, upon the date of the online publication of the results of the primary study aims: Patient-reported outcomes: All patient-reported outcomes will be de-identified and shared in raw form. Measures of treatment engagement: Deidentified values (e.g. number of treatment sessions attended) will be shared in raw form. Audio-video recordings of therapy sessions: These will be used in planned future research. Upon publication of a manuscript referencing these data, deidentified subject-level summary statistics (e.g., metrics of patient-provider vocal synchrony) will be shared.

Time frame: Complete, clean, de-identified copies of the data components described above, along with data dictionaries and metadata, will be publicly posted along with data use agreements by the online publication date of the primary aims in a peer-reviewed journal.

Access criteria: Data Use Agreements will ask users to not attempt to re-identify participants, either by merging in administrative, census, medical, or other data, or by using a software program that might re-identify participants. Investigators will consult as needed with the Cornell Research Data Management Service Group (RDMSG). As described in the Cornell Roybal Center overall data sharing plan, through the Cornell Roybal Center Investigator Development Program investigators will be able to access instruction and assistance to meet other requests for information that ensure research transparency and reproducibility: documentation about study aims; hypotheses/research questions; variable sources (e.g. outcome variables, covariates); measure/index construction; and publication information.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Aug 2025, 28 months.

Results were first posted in Oct 2026, 1 year 2 months after primary completion.

Of 1,297 non-industry interventional studies with no phase under Chronic Pain, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's 28 months is above that.

Counting every sponsor, half of 1,380 studies reached it within 20 months; a quarter within 9 and three quarters within 38.

Completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Aug 2026, on Oct 27, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2023
First posted
Apr 19, 2023
StartActual
Apr 12, 2023
Primary completionActual
Aug 25, 2025
CompletionActual
Aug 19, 2026was Sep 2026
Results first posted
Oct 27, 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 27, 2026
Results
Results posted
posted Oct 27, 2026
Study completion
Sep 2026→Aug 19, 2026 (actual)
Oct 27, 2026
Enrollment
150→165
Oct 27, 2026
Primary outcomes
1 edited, 1 time frame changed, 1 description edited
What changed in the outcomes
  • EditedPain intensityIntensityTime frame: Primary time point is the day after post-treatment, 1.5 months on average
  • Time frameSession AttendanceThis value will be calculated a day after post-treatment for the last participant, approximately 1 year from the start of enrollment → Assessed the day after post-treatment, an average of 1.5 months after randomization.
  • DescriptionSession Attendance: how it is measured was reworded
Oct 27, 2026
Documents
Secondary outcomes
4 edited, 1 removed, 4 description edited
What changed in the outcomes
  • EditedPain interferenceInterferenceTime frame: Primary time point is the day after post-treatment, 1.5 months on average
  • EditedSleep qualityDisturbanceTime frame: Primary time point is the day after post-treatment, 1.5 months on average
  • EditedClient satisfactionSatisfactionTime frame: Primary time point is the day after post-treatment, 1.5 months on average
  • EditedChange in Pain Medication UseTime frame: Primary time point is the day after post-treatment, 1.5 months on average
  • RemovedPhysical Activity LevelsTime frame: Primary time point is the day after post-treatment, 1.5 months on average
  • DescriptionAnger: how it is measured was reworded
  • DescriptionAnxiety: how it is measured was reworded
  • DescriptionDepression: how it is measured was reworded
  • DescriptionPositive Affect: how it is measured was reworded
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Active, not recruiting→Completed
    Results posted
    Study completion Sep 2026→Aug 19, 2026 (now actual)
    Enrollment 150→165
    Primary outcomes 1 edited, 1 time frame changed, 1 description edited
    What changed in the outcomes
    • EditedPain intensityIntensityTime frame: Primary time point is the day after post-treatment, 1.5 months on average
    • Time frameSession AttendanceThis value will be calculated a day after post-treatment for the last participant, approximately 1 year from the start of enrollment → Assessed the day after post-treatment, an average of 1.5 months after randomization.
    • DescriptionSession Attendance: how it is measured was reworded
    Secondary outcomes 4 edited, 1 removed, 4 description edited
    What changed in the outcomes
    • EditedPain interferenceInterferenceTime frame: Primary time point is the day after post-treatment, 1.5 months on average
    • EditedSleep qualityDisturbanceTime frame: Primary time point is the day after post-treatment, 1.5 months on average
    • EditedClient satisfactionSatisfactionTime frame: Primary time point is the day after post-treatment, 1.5 months on average
    • EditedChange in Pain Medication UseTime frame: Primary time point is the day after post-treatment, 1.5 months on average
    • RemovedPhysical Activity LevelsTime frame: Primary time point is the day after post-treatment, 1.5 months on average
    • DescriptionAnger: how it is measured was reworded
    • DescriptionAnxiety: how it is measured was reworded
    • DescriptionDepression: how it is measured was reworded
    • DescriptionPositive Affect: how it is measured was reworded
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05820204
Responsible party
Sponsor
First posted
Apr 19, 2023
Start date
Apr 12, 2023
Primary completion
Aug 25, 2025
Completion
Aug 19, 2026
Results posted
Oct 27, 2026
Last update
Oct 27, 2026

Study contacts

M. Cary Reid, MD, PhD
principal investigator · Weill Medical College of Cornell University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion